title: Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
abstract: BACKGROUND
  Anxiety, depression, and impaired health-related quality of life (HRQoL) are common in patients with psoriasis.
  
  
  OBJECTIVE
  We sought to analyze the effect of ustekinumab on these conditions in patients with moderate-to-severe psoriasis.
  
  
  METHODS
  Patients with moderate-to-severe psoriasis (n = 1230) were randomized 1:1:1 to receive 45 mg of ustekinumab, 90 mg of ustekinumab, or placebo. The Hospital Anxiety and Depression Scale was used to measure anxiety and depression, and the Dermatology Life Quality Index to measure HRQoL.
  
  
  RESULTS
  At baseline, 40.3% and 26.7% of patients reported symptoms of anxiety and depression, respectively, and 54.6% reported Dermatology Life Quality Index scores greater than 10, indicating a very high impact of disease on HRQoL. Greater improvements at week 12 in mean Hospital Anxiety and Depression Scale-Anxiety (13.9%), Hospital Anxiety and Depression Scale-Depression (29.3%), and Dermatology Life Quality Index (76.2%) scores were reported in ustekinumab groups compared with placebo (P < .001 each).
  
  
  CONCLUSIONS
  Results for these measures are reported only through 24 weeks.
  
  
  CONCLUSIONS
  Patients receiving ustekinumab reported significant improvements in symptoms of anxiety, depression, and HRQoL.
authors.affiliation: Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Richard G
authors.initials: RG
authors.lastname: Langley
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
authors.forename: Chenglong
authors.initials: C
authors.lastname: Han
authors.forename: Brad
authors.initials: B
authors.lastname: Schenkel
authors.forename: Philippe
authors.initials: P
authors.lastname: Szapary
authors.forename: Ming-Chun
authors.initials: MC
authors.lastname: Hsu
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Ortonne
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Gordon
authors.forename: Alexa B
authors.initials: AB
authors.lastname: Kimball
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001007:Anxiety / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D011788:Quality of Life; D012016:Reference Values; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab